Tyrosine kinase inhibitors' blood level monitoring and response to treatment in patients with Chronic Myeloid Leukemia for population characterization of patients and correlation between the evaluated parameters and disease evolution.
Several studies have suggested that treatments with decreasing imatinib mesylate's dosing, starting in 800 mg / day to 400 mg / day present better response to treatment of chronic phase CML. These results have been obtained by monitoring blood levels of imatinib and comparison to response indicators to imatinib or other TKI, as Hematologic Response (HR) Cytogenetic Response (CR) and Molecular Response (RM) BCR-ABL / control gene [Larson, 2008]. Thus, there are evidences that the evaluation of the relationship between the dose of imatinib or other ITQ (as well as blood levels) and the effectiveness of treatment, as measured by the cytogenetic and molecular responses, is a way to make the adjustment of the dose reducing side effects, and cost of treatment. This study aims to obtain blood levels data of the drugs and the molecular response in the population, in an attempt to relate the two results in the study population, in order to promote the correct dose adjustment. (AU)
Articles published in Agência FAPESP Newsletter about the research grant: